BioCardia, Inc. Common Stock
BCDAStock
$0.85−61.57%52W
Market Cap$13.06M
P/E—
Div yield—
Beta0.46
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-42.57%
Price vs S&P 500 (4W)0.42%
VGM Score18.75
Market Capitalization$13.06M
Earnings Surprise History
Q1 26-0.21est. -0.17
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.13
4.13
4.13
4.13
Industry Peers — Biological Products(180)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
BCDABioCardia, Inc. Common Stock | D | F | F | $0.85 |
| AMGNAmgen Inc | C | C | C | $371.58 |
| GILDGilead Sciences Inc | C | B | C | $136.30 |
| ARGXargenx SE American Depositary Shares | D | A | B | $857.97 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $179.18 |
| BIIBBiogen Inc. Common Stock | B | D | B | $208.92 |
| BNTXBioNTech SE American Depositary Share | C | C | C | $91.56 |
| MRNAModerna, Inc. Common Stock | D | B | B | $63.15 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $171.55 |
| EXELExelixis Inc | C | B | B | $55.68 |
| TECHBio-Techne Corp. | D | C | B | $71.77 |
About
BioCardia is a clinical-stage company developing cell-based therapeutics for cardiovascular and pulmonary diseases with unmet medical needs. Its CardiAMP platform delivers autologous mononuclear cells derived from bone marrow to treat ischemic heart failure with reduced ejection fraction and refractory angina, while its CardiALLO platform uses off-the-shelf allogeneic mesenchymal stem cells for ischemic heart failure and acute respiratory distress syndrome. CardiALLO is currently enrolling patients in clinical trials.